Combination of Paclitaxel, Ifosfamide, and Cisplatin Is an Effective Second-Line Therapy for Patients With Relapsed Testicular Germ Cell Tumors

Abstract

Four cycles of TIP as second-line therapy achieved a durable CR rate in a high proportion of patients with relapsed testicular GCT. The high CR rate emphasizes the importance of patient selection according to prognostic factors to achieve a favorable outcome to conventional-dose salvage therapy.

Salvage chemotherapy with high-dose carboplatin plus etoposide and autologous peripheral blood stem cell transplant in male pure choriocarcinoma: a retrospective analysis of 13 cases

“…Thirty-two patients were longterm cNED, but all the seven choriocarcinoma syndrome patients died. 23 We reported a series of 184 GCTs treated with salvage HDCT at Indiana University Hospital. One hundred and sixteen of these patients (63%) are alive and cNED.…”

“…Patients who progress after first-line chemotherapy are treated with second-line therapy for GCT. Several regimens can be used, including standard dose regimens with cisplatin þ ifosfamide þ either vinblastine 22 or paclitaxel 23 or HDCT with PBSC transplantation. 13 Recurrent pure choriocarcinoma has a very poor prognosis.…”

Late recurrence of an embryonal carcinoma of the testis. Case report

“…In case of relapse, favorable prognosis is predicted by complete resection (< 10% viable malignant cells), a good IGCCCG score at presentation, and possibly a longer platinumfree interval [3,4,7,[13][14][15][16]. Multimodality salvage therapy (conventional-dose chemotherapy and surgery) is still expected to cure approximately 25% of relapsed NSGCTs and ensure long-term remissions in 50% of patients [3].…”

A single-centre analysis of 30 patients with relapsed germ cell tumours treated with the TI-CE regimen

“…1 Options for the treatment of patients with primary resistant or relapsed disease include second-line regimens of conventional-dose chemotherapy (CDCT) combining cisplatin and ifosfamide with either vinblastine 2 or paclitaxel 3 or, alternatively, high-dose chemotherapy (HDCT) with autologous stem cell support (autoSCT). 4,5 In the absence of conclusive evidence from clinical trials, the precise indications for the use of HDCT and autoSCT remain unclear.…”